Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Postmenopausal Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity and Basal Metabolic Rate in Postmenopausal Women

NCT01550536
View directory record Official record
Conditions
Postmenopausal Metabolic Health
Interventions
Resistance and aerobic exercise
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 120 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
3
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

NCT01438073
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Healthy Postmenopausal Women, Agonadism
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

NCT01740427
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD-0332991, Letrozole, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
136
States / cities
Bellflower, California • Beverly Hills, California • Fullerton, California + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 6, 2026, 4:52 PM EDT
Withdrawn Phase 2 Interventional

A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women

NCT00787358
View directory record Official record
Conditions
Hip Fracture
Interventions
ZT-031, placebo
Drug · Other
Lead sponsor
Zelos Therapeutics
Industry
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Sep 6, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Calcium Absorption in Postmenopausal Thai Women

NCT02291315
View directory record Official record
Conditions
Fractional Calcium Absorption
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
53 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer

NCT01808040
View directory record Official record
Conditions
Post Menopausal, Hormone Receptor Positive Breast Cancer
Interventions
TAK700
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

NCT01923168
View directory record Official record
Conditions
Breast Cancer
Interventions
alpelisib, buparlisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 6, 2026, 4:52 PM EDT
Completed No phase listed Observational

Characterizing the Microbiome in Postmenopausal Women With Vulvar Lichen Sclerosus

NCT05147129
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Female only
Enrollment
17 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Pulse Consumption on Bone Health of Postmenopausal Women

NCT04692298
View directory record Official record
Conditions
Menopause
Interventions
pulses
Other
Lead sponsor
Oklahoma State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

NCT02478879
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
ZP-PTH, FORTEO
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Women's Isoflavone Soy Health (WISH) Trial

NCT00118846
View directory record Official record
Conditions
Atherosclerosis
Interventions
25 gm soy protein supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of Southern California
Other
Eligibility
30 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Not applicable Interventional

Prevention of Osteoporosis in Breast Cancer Survivors

NCT00567606
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Strength/Weight Training & Drug/Supplement, Drug/Supplement only
Other · Combination Product
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Kearney, Nebraska • Lincoln, Nebraska • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Combination Osteogenic Therapy in Established Osteoporosis

NCT00018447
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
PTH 1-34, MFPSR-fluoride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Results available

Preventing Recurrent UTI With Vaginal Estrogen

NCT05551949
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Urinary Tract Infections, Cystitis Recurrent
Interventions
Vaginal estradiol tablets
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
55 Years to 100 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 6, 2026, 4:52 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial Assessing Safety of MF101 for Hot Flushes

NCT01300078
View directory record Official record
Conditions
Hot Flashes
Interventions
MF101
Drug
Lead sponsor
Bionovo
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
4
States / cities
Berkeley, California • Lincoln, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 2 Interventional

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

NCT00107016
View directory record Official record
Conditions
Breast Neoplasm
Interventions
RAD001, Letrozole 2.5mg, Letrozole 2.5mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Springdale, Arkansas • Long Beach, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Protocol for Women at Increased Risk of Developing Breast Cancer

NCT00291135
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole
Drug
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Sep 6, 2026, 4:52 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Circadian Rhythms in Postmenopausal Women

NCT04893226
View directory record Official record
Conditions
Metabolic Syndrome, Postmenopausal Symptoms
Interventions
Time-Restricted Feeding (TRF)
Behavioral
Lead sponsor
Julie Pendergast
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 6, 2026, 4:52 PM EDT
Terminated Phase 2 Interventional Results available

Exemestane-RAD001-Metformin

NCT01627067
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Exemestane, Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

NCT05438303
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 6, 2026, 4:52 PM EDT
Recruiting Not applicable Interventional

BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women

NCT07413705
View directory record Official record
Conditions
Depressive Symptoms, Urinary Incontinence, Sexual Dysfunction
Interventions
EXOMIND (BTL-699-2) Active Treatment, EMSELLA (HPM-6000UF) ActiveTreatment, EXOMIND (BTL-699-2) Sham Treatment, EMSELLA (HPM-6000UF) Sham Treatment
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
40 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Winter Garden, Florida • Wellesley, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 6, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

NCT00592839
View directory record Official record
Conditions
Nocturnal Vasomotor Symptoms
Interventions
SCE-B, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
17
States / cities
Anaheim, California • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 6, 2026, 4:52 PM EDT
Recruiting Not applicable Interventional

Improving Outcomes in Early Menopause After Cancer

NCT06982677
View directory record Official record
Conditions
Early Menopause, Cancer, Premature Menopause, Surgical Menopause
Interventions
Nurse Navigator Intervention, Education Control
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 6, 2026, 4:52 PM EDT